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Background: In areas mesoendemic for malaria transmission, symptomatic individuals play a significant role as
reservoirs for malaria infection. Understanding the pathogenesis of symptomatic malaria is important in devising
tools for augmenting malaria control. In this study, the effect of TLR9 polymorphisms on susceptibility to
symptomatic malaria was investigated among Ghanaian children.
Methods: Four hundred and twenty nine (429) healthy Ghanaian children, aged three to eleven years (3–11 years),
were enrolled into a cohort study and actively followed up for symptomatic malaria for one year. Four TLR9 single
nucleotide polymorphisms (SNPs) namely: rs187084 (C-1486 T), rs5743836(C-1237 T), rs352139 (G + 1174A) and
rs352140 (G + 2848A) were genotyped by direct sequencing, and their attributable and relative risks for
symptomatic malaria determined. TLR9 haplotypes were inferred using the PHASE software and analysed for the
risk of symptomatic malaria. A luciferase assay was performed to investigate whether the TLR9 haplotypes influence
TLR9 promoter activity.
Results: The rs352139 GG genotype showed a significantly increased relative risk of 4.8 for symptomatic malaria
(P= 0.0024) and a higher mean parasitaemia (P= 0.04). Conversely, the rs352140 GG genotype showed a
significantly reduced relative risk of 0.34 (P= 0.048). TLR9 haplotypes analyses showed that TTAG haplotype was
significantly associated with reduced relative risk of 0.2 for symptomatic malaria (P= 4×10-6) and a lower mean
parasitaemia (0.007), while CTGA haplotype had an increased relative risk of 3.3 (P= 0.005). Functional luciferase
reporter gene expression assay revealed that the TTA haplotype had a significantly higher promoter activity than
the CCG, CTG and TCG haplotypes.
Conclusions: Taken together, these findings indicate a significant association of TLR9 gene polymorphisms with
symptomatic malaria among Ghanaian children in Dangme-West district.
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Despite the tremendous achievements in malaria control
over the past few years, malaria still remains a major
public health problem in the endemic countries. Accord-
ing to the WHO world malaria report, there were an
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reproduction in any medium, provided the or781,000, respectively, in the year 2009 [1]. Malaria has
a wide spectrum of infections that ranges from asymp-
tomatic malaria, symptomatic (mild) malaria, to severe
(complicated) malaria infections. Although severe mal-
aria, which constitutes 1-2% of all malaria cases, is
responsible for most of the malaria deaths, symptomatic
malaria accounts for the major burden of the disease’s
morbidity [2]. Moreover, while asymptomatic gameto-
cyte carriers are the major transmission reservoir in
areas hyperendemic for malaria [3], symptomatic indi-
viduals play an increased role as reservoir for malariatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mission [4].
Among the factors that have been postulated to deter-
mine the clinical outcome of malaria infections are host
genetic make-up and immunity [5]. The contribution of
genetics in susceptibility to malaria has been well docu-
mented, with the sickle cell trait, haemoglobin C variants
and glucose-6-phosphate dehydrogenase deficiency con-
ferring protection against severe malaria [6]. On the
other hand, α-thalassaemia shows a more complex effect
of increasing susceptibility to mild malaria while confer-
ring protection against severe malaria [7]. Thus, it is
possible that the mechanism responsible for protection
against mild and severe malaria may be different from
each other. This hypothesis has been reinforced by the
fact that in malaria endemic areas, immunity to severe
malaria is achieved at a time when susceptibility to mild
malaria is still high [8].
Toll like receptors (TLR) are innate immune receptors
that recognize pathogen associated molecular patterns
and trigger activation of the intracellular signal cascade
that induces transcription of inflammatory cytokines,
type 1 interferons and chemokines [9]. In addition,
stimulation of TLRs also leads to dendritic cell matur-
ation and induction of adaptive immune response [10].
TLR2 and TLR4 have been reported to recognize Plas-
modium falciparum glycosylphosphatidylinositol (GPI)
[11], while TLR9 has been reported to recognize malaria
haemozoin [12] and/or Plasmodium DNA-bound hae-
mozoin [13].
TLR9-encoding gene is located on chromosome
3p21.3 and spans approximately 5 kb. It consists of 2
exons and encodes 1032 amino acids [14]. The TLR9
gene has been implicated in pathogenesis of severe
malaria both in murine model and in humans. In animal
studies, it has been demonstrated that mice deficient in
TLR9 survived cerebral malaria better than the wild type
mice [15] and inhibition of TLR9 activations by TLR9
agonist conferred protection against cerebral malaria in
mice [16]. A number of single nucleotide polymorphisms
(SNPs) for TLR9 have been identified, and four of these
SNPs; rs187084, rs5743836, rs352139 and rs352140, have
been reported to show high heterozygocity among three
major US ethnic groups [17]. Several studies have
focused on the relationship of TLR9 polymorphisms and
severe malaria phenotypes, with some reporting positive
association. For example, in a study in Ghana on malaria
in pregnancy (n = 304), the TLR9 promoter polymorph-
ism rs187084 C allele was associated with increased risk
of low birth weight among term infants [18], while a
Brazilian study among adults (n = 304) with mild malaria
associated the promoter polymorphisms rs187084 C
allele and rs5743836 C allele with high parasitaemia
(>10,000 parasite/μl) [19]. However, these effects ofTLR9 promoter polymorphisms on severe malaria phe-
notypes were not replicated in a large family and popula-
tion-based association study from Malawi and Gambia
(n> 6000) that found no convincing association of the
four common TLR9 SNPs with severe malaria [20]. On
the other hand, few studies have focussed on the effect
of TLR9 polymorphisms on susceptibility to mild mal-
aria. Two studies, carried out in Brazil [19] and Iran
[21], reported no influence of TLR9 promoter poly-
morphism on susceptibility to mild malaria in their
respective populations. However, the effect of TLR9
polymorphisms on mild malaria among the African
population is not well understood.
In the present study, healthy Ghanaian children living
in an area mesoendemic for malaria transmission were
recruited into a prospective cohort study for one year,
and the effect of the TLR9 SNPs on susceptibility to
symptomatic malaria investigated.
Methods
Study area and subjects
Details about the study area, population, set-up of the
cohort and the follow-up protocol has previously been
described [22]. In brief, the cohort study was conducted
at Asutuare, a sub-district of Dangme-West District
in the Great Accra region of Ghana. The district has
two rainy seasons in a year, April to July and October to
December, and consequently malaria transmission is sea-
sonal, with the peak transmission coinciding with the
period of the major rainy seasons while the dry seasons
having low malaria transmission [23]. It is estimated that
individuals in Dodowa, (the district headquarter for
Dangme-West district), are exposed to about 20 infective
bites per year, and 98% of the infections are due to
P. falciparum [23]. Four hundred and twenty nine (429)
healthy Ghanaian children, aged 3–11 years, were enrol-
led into a one-year prospective cohort study, from June
2007 to July 2008, which spanned across three (3) rainy
seasons. Only one child per household was recruited in
order to avoid inclusion of closely related individuals.
The study participants were actively followed up for clin-
ical malaria symptoms with regular home visits of two-
week intervals. During the visits, data on the health
status of the participants for the previous two weeks were
collected using a standard questionnaire and their body
temperatures measured. Individuals suspected of clinical
malaria were referred to the community health centre
where medical examinations and blood smear for malaria
were carried out and treatment given according to the
recommendation of the Ghanaian Ministry of Health.
Phenotype definition
In this study, a participant was considered to be suffer-
ing from symptomatic mild malaria, if he or she had a
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parasite load that is greater than or equal to 5,000 parasite
per microliter (μl) of blood. Informed consent was
obtained from each participant’s parents/guardian after a
detailed explanation of all procedures in the study. The
study was approved by the Ghanaian Ministry of Health,
Institutional Review Board (IRB) of Noguchi Memorial
Institute of Medical Research, University of Ghana and
IRB of Institute of Tropical Medicine, Nagasaki University.
DNA extraction and polymerase chain reaction (PCR)
Sample collection and storage has been described in
detail elsewhere [22]. Genomic DNA was extracted
from blood sample using QIAamp DNA blood mini kit
(Qiagen, Tokyo, Japan).
The PCR amplification for the rs187084, rs5743836,
and rs352139 were carried out using the forward
primer 5′-CTGTGGACATCGATATCGGTGT-3′ (PF3)
and reverse primer 5′-AAGCTTCGCTGCGGCAGAA
ACCCTGT-3′ (i1R), while for rs352140; forward primer
5′-TCTAGACATCATGCTGGCCATGACC-3′ (2 F8)
and reverse primer 5′-CAGAGCCACTCAACAGTG
GACT-3′ (2R5) were used. Each PCR reaction contained
5.0 μl of 2xKOD FX buffer, 2.0 μl of 2 mM dNTP, 0.4 μl
of forward primer, 0.4 μl of reverse primer, 0.2 μl of
KOD Polymerase, 1.5 μl of water, and 0.5 μl of DNA and
the PCR conditions used were as follows: One cycle at
95°C for 5 min, 35 cycles at 95°C for 1 min, 35 cycles at
64°C for 1 min, and one cycle at 72°C for 4 min.
SNP genotyping
The TLR9 SNPs studied were identified by analysis
of direct nucleotide sequencing of PCR products.
The sequencing was carried out using the 3730
DNA Analyzer Applied Biosystems sequencing ma-




rs5743836, rs352139 and rs352140, respectively. The
sequencing data was analysed using sequence scan-
ner version 1.0, Applied Biosystems.
Plasmid construction for luciferase gene reporter assay
Using the PCR primers PF3 and i1R (named above) a
DNA fragment, nucleotide positions −2268 to +1233
(NM_17442), which encompassed the promoter, exon 1
and intron 1 regions of the TLR9 gene was amplified
from genomic DNA of four selected study subject. The
four subjects were homozygous carriers of TTA, CTG,
TCG, and CCG for SNPs at positions −1486, -1237 and
+1174, respectively. Topo cloning of the PCR products
were carried out using Zero bluntW TopoW cloning kit
and transformed into One ShotW TOP10 Competentcells. Positive clones were selected, plasmid extracted and
presence of the expected fragment confirmed by restric-
tion digestion analysis and DNA sequencing. The cloned
fragment was then treated with BamHI, HindIII and BclI
restriction enzymes to obtain a 2754-bp DNA fragment,
nucleotide position (−1521 to +1233). This fragment was
then cloned into BglII and HindIII restriction sites of
the firefly luciferase reporter vector pGL4.10 (Promega,
Madison, WI) resulting in construction of four (4)
promoter-intron plasmids (Figure 1a). The presence of
the insertions and their orientation were confirmed by
restriction digestion analysis and DNA sequencing.
Transient transfection assay
THP-1 (human acute monocytic leukaemia) cells were
obtained from the American type culture collection
(ATCCW) and cultured as per their instructions in
RPMI-1640 medium supplemented with 10% foetal calf
serum (FCS) and Antibiotic-Antimycotic, 100X (AAS)
(Gibco, Life technologies). After more than 90% conflu-
ence was achieved in a cell culture flask, 1 × 106 cells/
well were then seeded into a 24-well plates; and transi-
ently transfected with 2 μg of each of the four TLR9
plasmid constructs (designated as TTA, CCG, CTG and
TCG promoter-intron plasmids) and 2 μg of an empty
pGL4.10 vector (promega) as a negative control. All the
transfections were performed using Fugene HDW (Pro-
mega) according to the manufacturer’s recommenda-
tions. After 48 h of incubation, the cells were transferred
from the 24-well plate to 1.5 ml micro-centrifuge tubes,
centrifuged at 200 rpm for 5 min and washed with 1 ml
of phosphate buffered saline (PBS). The cells were lysed
by incubation with passive lysis buffer (promega) for
15 min at room tempreture, harvested and cleared by
centrifugation at 15,000 rpm for 3 min. Luciferase activ-
ity of three independent transfections were determined
in wallac 1420 multilabel counterW (Perkin Elmer) using
luciferase assay systems (promega). All transfections
were performed in triplicate.
Statistical analysis
Data were analysed with GraphPad prism (Software
version 5.00, Inc; San Diego California USA). TLR9
SNPs genotype and allele frequencies were calculated
by direct counting. Consistency of genotype frequency
with Hardy-Weinberg Equilibrium (HWE) was deter-
mined by comparing the observed number of different
genotypes with those expected under the HWE for the
estimated allele frequency [24].
The incidence, attributable risk, relative risk and 95%
confidence intervals (CIs) were calculated and their signif-
icances tested using t-statistics. The p value of <0.05 was
considered to be significant after Bonferroni’s corrections
































Figure 1 Luciferase reporter activity of TLR9 (promoter-intron) plasmid constructs. a), schematic of four reporter gene constructs that
contains TLR9 promoter- intron region with TTA, CCG, CTG and TCG at position −1486, -1237, and +1174 polymorphic sites, respectively. b),
luciferase expression of the four constructs in THP-1 cells and pGL4.10 as negative control. The luciferase activity levels are mean values of three
(3) independent experiments that were all carried out in triplicate. Anova test and t-test were used to test for statistical significance. P value of
<0.05 was considered to be statistically significant.
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number of events in the adjusted observation period
(person per year) for each genotype or haplotype. The
attributable risk was calculated by subtracting the inci-
dence of symptomatic malaria in non-carriers of a geno-
type/haplotype from carriers of the genotype/haplotype,
while the relative risk was calculated by dividing the inci-
dence of symptomatic malaria for a genotype/haplotype
with that of non-carriers of the genotype or haplotype aspreviously described [25]. Statistical significance of at-
tributable risk was evaluated by assuming null hypo-
thesis, that attributable risk follows normal distribution
N(0, SE), where SE was estimated by the formula
described in reference [25].
Haplotypes for TLR9 SNPs were estimated from non-
phased genotype data with maximization likelihood algo-
rithm by the use of PHASE version 2.1.1 [26,27]. Also,
pairwise linkage disequilibrium between each pair of
Figure 2 Schematic drawing of the Toll-Like Receptor 9 gene structure and positions of the four TLR9 SNPs. The four SNPs studied are
located at position −1486, -1237, +1174 and +2848, respectively. The positions were calculated by taking the A of TLR9 ATG start codon as
position 1 based on Genbank accession no. NM_17442.
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The heterogeneity of mean parasite density for different
genotype carriers was determined by Analysis of variance
(ANOVA), then the genotype effect assessed with stu-
dent’s t-test comparing mean parasite density between
carriers and non-carriers of each genotype.
Results
TLR9 genotype frequencies
In this study, four common TLR9 SNPs, (two located in
the promoter region, one intronic and one in the coding
region of the second exon (Figure 2)), were genotyped
by direct sequencing for the 429 Ghanaian cohort chil-
dren who were successfully followed up for one year.
The minor allele frequencies for rs187084 (C-1486 T),
rs5743836(C-1237 T), rs352139 (G+ 1174A) and
rs352140 (G+ 2848A) were found to be 0.35, 0.38, 0.41
and 0.25, respectively, in our study population. The
genotype distributions of all the SNPs examined did not
show significant deviation from HWE.
Linkage disequilibrium
Pairwise linkage disequilibrium (LD) for the four SNPs
was analysed using haploview software and a weak LD
was observed between the SNPs rs352139 and rs352140
(D1 = 1, r2 = 0.237); rs352139 and rs5743836 (D1 = 0.857,
r2 = 0.319); and rs352139 and rs187084 (D1 = 0.846,
r2 = 0.277) (Table 1).Table 1 The strength of pairwise linkage disequilibrium
for the four TLR9 SNPs analysed in the study
r2
D1
rs352140 rs352139 rs5743836 rs187084
rs352140 0.237 0.032 0.175
rs352139 1.0 0.319 0.277
rs5743836 0.4 0.857 0.014
rs187084 0.535 0.846 0.124
D1 is the measure for deviation of the observed haplotype frequency from the
expected frequency, with D1 =1 showing that the examined loci are
completely dependent on one another. r2 is the correlation coefficient
between pair of two loci and r2> 0.4 showing a meaningful association while
r2> 0.2 being suggestive.Effect on incidence of symptomatic malaria
Assessment of the effect of TLR9 genotypes on the risk
of symptomatic mild malaria was carried out by calculat-
ing the incidence of malaria, the relative risk and attrib-
utable risk for each TLR9 genotype studied (Table 2).
The assessment revealed that the GG genotype for the
rs352139 (G+ 1174A) intronic SNP increased the attrib-
utable risk for malaria by 0.116 events per person per
year, with an incidence of 0.146 vs. 0.03 for rs352139
GG vs. non-GG carriers, respectively, and a significant
relative risk of 4.8 even after Bonferroni’s correction
for multiple testing (pcorrected = 0.0024) (Table 2). In
contrast, the rs352140 (G + 2848A) GG genotype
decreased the attributable risk by 0.076 events per per-
son per year, with an incidence of 0.04 vs. 0.116
for rs352140 GG vs. non-GG carriers, respectively,
and a significant relative risk of 0.34 (pcorrected = 0.048)
(Table 2). The promoter polymorphisms rs187084
(C-1486 T) and rs5743836(C-1237 T) did not show a
significant influence on the incidence of symptomatic
malaria in the study population (Table 2).Influence on parasitaemia
The influence of TLR9 polymorphisms on parasitaemia
was evaluated by comparing the mean parasite densities
at the point of febrile episodes among carriers of each
genotype. It was observed that individuals with rs352139
(G+1174A) GG genotype had a significantly higher mean
parasitaemia level compared with non-GG (GA+AA)
genotype (19,376 vs. 6,086 parasite/μl, respectively,
p = 0.01) (Figure 3a), while individuals with the rs5743836
(C-1237 T) TT genotype had a significantly lower mean
parasite load compared with the non-TT (TC+CC) geno-
type (5,501 vs. 16,973 parasite/μl, respectively, p = 0.03)
(Figure 3)b. No effect on mean parasitaemia was detected
for the TLR9 SNPs rs187084 (C-1486 T) and rs352140
(G+2848A) (Figure 3c and 3d).TLR9 haplotype analysis
Eleven (11) TLR9 haplotypes were inferred using the
Phase software and their estimated haplotype frequencies
Table 2 Incidence, relative risk and attributable risk of mild malaria among carriers of TLR9 SNP’s genotypes
aSNPs Incidence Relative risk Attributable risk bCI p value cpc
rs187084(C-1486 T)
TT vs. CC+ TC 0.04 0.37 −0.061 (−0.11)-(−0.01) 0.01 ns
CC vs. TT + TC 0.20 3.7 0.144 0.03-0.26 0.01 ns
rs5743836(C-1237 T)
TT vs. CC+ TC 0.04 0.38 −0.060 (−0.11)-(−0.01) 0.01 ns
CC vs. TT + TC 0.09 1.29 0.020 (−0.05)-(0.09) 0.6 ns
rs352139(G + 1174A)
GG vs. AA +GA 0.15 4.8 0.116 0.05-0.18 0.0003 0.0024
AA vs. GG+GA 0.03 0.3 −0.055 (−0.10)-(−0.01) 0.03 ns
rs352140 (G + 2848A)
GG vs. AA +GA 0.04 0.3 −0.076 (−0.13)-(−0.02) 0.006 0.048
AA vs. GG+GA 0.11 1.63 0.044 (−0.08)-(0.17) 0.5 ns
aSNPs: Single nucleotide polymorphisms; bCl: confidence intervals; cpc = corrected p value by bonferroni method by factor of 8; ns: not statistically significant.
The incidence shown is for the genotype highlighted in bold, the relative and attributable risk shown are for the same genotype when compared with the
non-carriers of the genotype. Corrected p value <0.05 was considered to be statistically significant.
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CTGA: 17.3%, TCGG: 15.1%, CCGG: 14.6%, TCGG:
5.9%, TTGG: 2.6%, CCAG: 2.0%, TTGA: 1.8%, CTGG:
1.1%, TCAG: 0.2% and CTAG: 0.2% (for rs187084 (C-
1486 T), rs5743836(C-1237 T), rs352139 (G+ 1174A)
and rs352140 (G+ 2848A), respectively). The major hap-
lotypes with frequencies greater than 5% were considered
for further analysis on their possible effect on the risksFigure 3 The distribution of mean parasitaemia for carriers of the TLR
(G + 1174A) GG, GA and AA genotypes are 19,376; 6,268; 5,589 parasite/μl o
parasitaemia compared with the non-GG genotype (19,376 vs. 6,086 parasi
(C-1237 T) CC, CT and TT genotypes are 23,532; 14,924; 5,501 parasite/μl of
lower parasitaemia compared with the non-TT genotype (5,501 vs. 16,973 p
rs187084 (C-1486 T) CC, CT and TT genotypes are 20,691; 10,089; 11,117 pa
rs352140 (G+ 2848A) GG, GA and AA genotypes are 10,738; 13776; 12088 p
and student’s t-test. P value of <0.05 was considered to be statistically signfor symptomatic malaria. The result revealed that the
TTAG haplotype significantly reduced the attributable
risk by 0.115 events per person per year, with an inci-
dence of 0.03 vs. 0.147 for carriers of TTAG vs. non-
TTAG haplotypes, respectively; and a significant relative
risk of 0.22 (pcorrected = 4×10
-6) (Table 3). Conversely, the
CTGA haplotype significantly increased the attributable
risk by 0.103 events per person per year, with an9 SNP genotypes 3a): The mean parasite load for the rs352139
f blood. The *GG genotype was significantly associated with higher
te/μl of blood, p = 0.01). 3b): The mean parasite load for the rs5743836
blood, respectively. The *TT genotype was significantly associated with
arasite/μl of blood, p = 0.03). 3c): The mean parasite load for the
rasite/μl of blood, respectively. 3d). The mean parasite load for the
arasite/μl of blood. Statistical analysis was performed using ANOVA
ificant.
Table 3 Incidence, relative risk and attributable risk of mild malaria among carriers of TLR9 haplotypes
aHaplotype Incidence Relative risk Attributable risk bCI p value cpc
TTAG vs. non-TTAG 0.03 0.2 −0.115 (−0.16)-(−0.07) 8x10-7 4x10-6
CTGA vs. non-CTGA 0.15 3.3 0.103 0.04-0.16 0.001 0.005
TCGG vs. non TCGG 0.10 1.5 0.032 (−0.03)-(0.09) 0.3 ns
CCGG vs. non-CCGG 0.12 2.1 0.063 0.0-0.1 0.05 ns
TCGA vs. non-TCGA 0.09 1.2 0.012 (−0.07)-(0.09) 0.8 ns
aHaplotype for rs187084 (C-1486 T), rs5743836 (C-1237 T), rs352139 (G + 1174A) and rs352140 (G + 2848A), respectively; bCl: confidence intervals; cpc = corrected
p value by Bonferroni’s method by a factor of 5; ns: not statistically significant. The incidence shown is for the haplotype highlighted in bold, the relative and
attributable risk shown are for the same haplotype when compared with the non-carriers of the haplotype. Corrected p value <0.05 was considered to be
statistically significant.
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non-CTGA haplotypes, respectively; and a significant
relative risk of 3.3 (pcorrected = 0.005) (Table 3). The other
three common haplotypes (TCGG, CCGG and TCGA)
were not observed to significantly influence the risk for
symptomatic malaria in our cohort study.
On analysing the effect of TLR9 haplotypes on parasit-
aemia, it was observed that the TTAG haplotype was
significantly associated with lower mean parasitaemia,
with carriers of TTAG having a mean parasite load of
6,178 parasite/μl compared with 20,114 parasite/μl of
the non-TTAG carriers (p = 0.007) (Figure 4). No signifi-
cant effect on parasitaemia was observed for the haplo-
types CTGA, TCGG, CCGG and TCGA in our study
population (Figure 4).
Luciferase reporter gene assay
To further examine the functional relevance of the hap-
lotypes in terms of the TLR9 gene transcription, four
promoter plasmids containing the TLR9 promoter, exon
1 and intron 1 regions were prepared (Figure 1a) and
transfected into THP-1 cells. The four constructs, repre-
sents the five major TLR9 haplotype in our population,
with TTA, CTG, TCG, and CCG SNPs at positions
−1486, -1237 and +1174, respectively (Figure 1a). All the
four constructs consistently showed a significant higher
relative luciferase activity than the negative control
(empty pGL4.10 vector). It was observed that the TTA
promoter plasmid has a significantly higher luciferase
activity compared with all the other three promoter plas-
mids, i.e. the CCG, CTG and TCG (P = 0.0001, P = 0.048
and P= 0.029, respectively) (Figure 1b). It was also
observed that the CTG promoter plasmid had a signifi-
cantly higher luciferase activity than the CCG promoter
plasmid (P = 0.015) (Figure 1b).
Discussion
The TLR9 polymorphisms have been postulated to have
a cis-regulatory effect on TLR9 expression [20] and also
shown to alter cytokine levels during severe malaria
infections [29]. In this study, the effect of TLR9 genepolymorphisms on symptomatic malaria was investi-
gated and TLR9 polymorphisms and haplotypes were
significantly associated with susceptibility to symptom-
atic malaria among Ghanaian children.
In this cohort study, the intronic polymorphism
rs352139 (G+ 1174A) GG genotype was significantly
associated with increased risk for symptomatic malaria
and high parasitaemia. Previous functional study has
reported that this intronic SNP has a regulatory effect
on TLR9 expression, with the rs352139 G allele in com-
bination with the promoter rs187084 (C-1486 T) C allele
having a down-regulatory effect, while the rs352139 A
allele in combination with rs187084 T allele having an
up-regulatory effect on TLR9 expression among patients
with systemic lupus erythematosus [30]. However, it is
currently not clear how this intronic SNP induces such a
phenotype change. It is possible that it influences signal-
ling by creating an alternative splicing site and thus,
affecting the mRNA transcription and the final protein
product. Equally, the rs352139 SNP could be a likely
marker in LD with a polymorphic regulatory region that
controls TLR9 expression or a functional coding region
SNP. In contrast to our finding, Campino et al [20]
reported an association of the rs352139 A allele with
severe malaria among Malawian population but not in
the Gambian population [20]. This discrepancy may in
part be explained by the difference in phenotypes and
populations examined, and also by the different role
pro-inflammatory cytokines play in the pathogenesis of
symptomatic and severe malaria. For example, an early
high IFN-γ response has been reported to confer protec-
tion against symptomatic malaria episodes [31,32], while
an over-production of IFN-γ has been associated with
susceptibility to cerebral malaria [33].
The synonymous coding SNP, rs352140 (G+ 2848A)
GG genotype was associated with protection from symp-
tomatic malaria but no such protective effect was
observed for parasitaemia among our cohort popula-
tion. This rs352140 SNP is linked to the rs352139
(G+ 1174A) (D1 = 1, r2 =0.237) in the study population,
with the rs352140 G allele linked to rs352139 A allele.
Figure 4 The distribution of mean parasitaemia for carriers of the TLR9 haplotypes. The mean parasite load for the haplotypes are TTAG,
CTGA, TCGG, CCGG and TCGA are 6,178; 15,992; 21,034; 15,631; 12,714 parasite/μl of blood. The *TTAG haplotype was significantly associated with
lower parasitaemia compared with the non-TTAG haplotype (6,178 vs. 20,114 parasite/μl of blood, p = 0.007). Statistical analysis was performed
using ANOVA and student’s t-test. P value of <0.05 was considered to be statistically significant.
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attributed to the effect of the rs352139 A allele which
has been shown to have an up-regulatory effect on TLR9
expression [30].
The promoter polymorphism rs5743836 (C-1237 T)
TT genotype was associated with low parasitaemia but
no effect on susceptibility to symptomatic malaria was
observed in this study. Our finding is consistent with
that of Leorrati et al [19] who reported an association of
rs5743836 TT genotype with low parasitaemia (<10000
parasite/μl) among adults with mild malaria in the
Brazilian Amazon [19]. The rs5743836 TT variant has
been shown to have a higher promoter activity than the
CC genotype [34], and thus, could result in increased
pro-inflammatory cytokine production during malaria
infection leading to successful control and elimination of
malaria parasites.
On haplotype analysis, the TLR9 TTAG (−1486 T,
-1237 T, +1174A, +2848 G) haplotype, the most fre-
quent haplotype (39.1%) in the study population, was
significantly associated with protection against symp-
tomatic malaria and high parasitaemia. These findings
were strongly supported by the result of luciferase
reporter gene expression assay which showed a signifi-
cantly higher promoter activity for the TTA (−1486 T,
-1237 T, +1174A) haplotype compared with the CCG,
CTG and TCG haplotypes (Figure 1b). It was also
observed that the CTG haplotype had a higher promoter
activity than the CCG haplotype (Figure 1b). Taken
together, the haplotype with A allele for rs352139 (TTA)
consistently had a significantly higher promoter effect
than all the haplotypes with G allele for the same SNP (i.e.CCG, CTG and TCG). It was also observed that the
haplotypes with T allele for rs5743836 (i.e. TTA, CTG)
had a higher promoter effect than those with C allele
for the same SNP (i.e. CCG, TCG) and that carriers of
the TTA haplotype had the highest promoter activity,
the CTG haplotype had an intermediate activity, and the
CCG having the lowest promoter activity. Thus, it is pos-
sible that these two SNPs (the rs5743836 (C-1237 T) and
rs352139 (G+ 1174A)) have a greater role of influencing
TLR9 gene transcription and expression. This luciferase
assay result is in agreement with the findings of Tao et al
2007, who reported that the rs187084 (C-1486 T) T allele
in combination with rs352139 (G+ 1174A) A allele had a
higher TLR9 expression compared with the rs187084 C
allele in combination with rs352139 G allele among
Japanese population who are not polymorphic for
rs5743836 (C-1237 T) (i.e. TTA had higher TLR9 expres-
sion than CTG) (31). Therefore, it can be inferred that
the TTAG haplotype may exert an increased TLR9 tran-
scriptional activity resulting in higher TLR9 expression
and subsequently higher pro-inflammatory cytokine pro-
duction, thus conferring protection against symptomatic
malaria phenotype. The TTAG haplotype has also been
associated with increased risk for meningococcal menin-
gitis among Dutch children [35] and also associated with
protection from ulcerative colitis among the Japanese
population [36]. The different effects of TLR9 haplotypes
in different disease phenotypes could be explained by
the different roles inflammatory cytokines play in patho-
genesis of these diseases. While robust pro-inflammatory
cytokines has been reported to provide protection against
clinical mild malaria [31] and against experimental colitis
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response has been identified as harmful and contributing
to tissue damage [38].
The major limitation of this study is the low incidence
of symptomatic malaria [22]. The study was conducted
in an area with low but perennial malaria transmission
with the intention of identifying clearly individuals sus-
ceptible or resistant to the symptomatic malaria pheno-
types. Nevertheless, this study has highlighted clearly
that the TLR9 gene polymorphisms significantly influ-
ence susceptibility to symptomatic malaria. It is there-
fore worthwhile to carry out more studies in areas with
different malaria transmission and using a larger sample
size, so that the role of TLR9 polymorphisms on differ-
ent malaria phenotypes can clearly be deciphered.
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